Drug intelligence / Profile preview

N-45a

Development stage: Preclinical
Lead developer: Neurocarrus
Modality: Recombinant Proteins and Enzymes

Overview

N-45a is an engineered recombinant protein biologic developed by Neurocarrus, specifically designed for proprioceptor repair. Proprioceptors are specialized sensory neurons that provide information about body position and movement; damage to these nerves can result in significant sensory and motor impairment, including loss of coordination and balance. N-45a utilizes Neurocarrus's proprietary protein engineering platform to target these specific nerve fibers and promote their regeneration or functional recovery. The asset is currently in the preclinical stage of development.

Beyond the preview

Go deeper on N-45a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-45a.

Explore the full profile